CryoLife (NYSE:CRY) has been upgraded from Neutral to Buy in a statement by Ladenburg Thalmann earlier today.
- Updated: February 17, 2017
Having a price of $16.10, CryoLife (NYSE:CRY) traded 5.59% higher on the day. With the last close down -4.17% from the two hundred day average, compared with the S&P 500 Index which has increased 0.06% over the same period. CryoLife has recorded a 50-day average of $18.78 and a two hundred day average of $17.74. Volume of trade was up over the average, with 196,731 shares of CRY changing hands over the typical 152,813
Ladenburg Thalmann has upgraded CryoLife (NYSE:CRY) from Neutral to Buy in a statement released on Friday February 17, 2017.
On 01/09/2017, Northland Securities released a statement on CryoLife (NYSE:CRY) upped the target price from $0.00 to $23.50 that suggested an upside of 0.24%.
With a total market value of $0, CryoLife has price-earnings ratio of 51.67 with a one year low of $10.04 and a one year high of $20.15 .
A total of 4 analysts have released a research note on CryoLife. Three firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $13.75.
About CryoLife (NYSE:CRY)
CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company's surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.